Please login to the form below

Not currently logged in
Email:
Password:

Valeant to buy Russian OTC pharma firm Natur Produkt

Further expands Canadian company’s presence in emerging markets

Valeant Pharmaceuticals has continued its run of acquisitions with the $180m purchase of Saint Petersburg-based specialty pharma firm Natur Produkt.

Valeant will take control of over-the-counter (OTC) brands such as AntiGrippin, a cough and cold remedy, as well as sore throat treatments Anti Angin, Sage and Eucaplyptus MA.

Natur Produkt, which markets its products mainly in Russia, had total revenues of around $65m furing 2011, with double digit growth expected in 2012, and Valeant said it expected the deal to close by the middle of 2012.

"We are pleased to add a leading consumer franchise to our growing operations in Russia," said J Michael Pearson, chair and CEO of Valeant.

"Not only is the OTC market very attractive in Russia due to the self-pay element, but it is also one of the fastest growth components of the Russian healthcare system.

“The addition of this high-growth operation, along with our previously announced acquisition of certain assets from Gerot Lannach, will bring our pro forma revenues in Russia to approximately $175m by the end of 2012."

The purchase of Natur Produkt is the second major move into Russia for Valeant this month following its purchase from Austria-based Gerot Lannach of a portfolio of generics products that are sold mainly in Russia and the Commonwealth of Independent States (CIS).

The latest deal also confirms the Canadian company's commitment to at least two of the emerging BRIC markets, following the company's recent moves in Brazil, where it took a minority stake in Pele Nova and purchased over-the-counter (OTC) medicine and dietary supplement manufacturer Probiotica.

• More details about the pharmaceutical market in Russia, including the impact of the recently implemented healthcare bill, can be found in PMGroup's webinar Russia: The inside story.

27th March 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Difference Collective

Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...